Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Teva Pharmaceutical Industries Ltd (NYSE:TEVA)

33.23
Delayed Data
As of Jan 20
 -0.24 / -0.72%
Today’s Change
33.16
Today|||52-Week Range
64.31
-8.33%
Year-to-Date
Teva's (TEVA) Pain Drug Vantrela ER Receives FDA Approval
Jan 19 / Zacks.com - Paid Partner Content
3 Top Dividend Stocks Selling for a Discount This Winter
Jan 09 / MotleyFool.com - Paid Partner Content
Lilly to Boost Migraine Pipeline with $960M CoLucid Buyout
Jan 19 / Zacks.com - Paid Partner Content
Stock Market News for January 09, 2017
Jan 09 / Zacks.com - Paid Partner Content
Lilly Wins Appeal Against Teva in Alimta Patent Lawsuit
Jan 13 / Zacks.com - Paid Partner Content
Impax (IPXL) Applies for Generic Aubagio; Sanofi Files Lawsuit
Jan 09 / Zacks.com - Paid Partner Content
Pharma Stock Roundup: Trump Targets Pharma Again, Merck Up on Keytruda News
Jan 13 / Zacks.com - Paid Partner Content
Teva Falls on Disappointing 2017 Sales & Earnings Guidance
Jan 09 / Zacks.com - Paid Partner Content
New Strong Sell Stocks for January 11th
Jan 11 / Zacks.com - Paid Partner Content
Trump threat fails to halt drug price hikes in 2017
Jan 04 / CNNMoney.com
Merrimack (MACK) Sells Onivyde Rights to Ipsen for $1B
Jan 09 / Zacks.com - Paid Partner Content